Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT03764137
Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer
Overview
This clinical study will investigate the utility of PET imaging with \[89Zr\]Panitumumab for imaging of EGFR expression in newly diagnosed colon cancer patients to assess lymph node involvement. If promising, this data will be used to design larger trials.
Sponsor
University of Alabama at Birmingham
Phase
Phase 1/2
Contacts
Suzanne Lapi, PhD (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT03764137Drug / Compound
Panitumumab
Isotope(s):
ZIRCONIUM-89
Radioisotope: Zr89
Theranostic Role: PET Imaging
T1/2 (Half-Life): 78 Hours
Decay Mode: POSITRON β+ (22%), ELECTRON CAPTURE (76%), GAMMA
Energy: max 0.9 MeV, E mean 397 keV, Gamma 511 keV
Range: N/A
Decay Daughters: Y89 (Stable)
Status: Clinical Trials Only
Target(s):
- EGFR
Ligand Class: Antibodies
Eligibility
Inclusion
- Scheduled to undergo surgical resection
- Diagnosis of colon cancer
Exclusion
- Weight over 350 lbs., due to the scanner bore size
- Inability to receive glucagon
- Inability to receive Eovist (gadoxetate disodium) gadolinium based contrast agent
- Finding or suspicion of distant metastases on CT
Share your feedback
Help us improve your experience